Anthera Pharmaceuticals Inc. stock rose 7.3% in pre-market trade Tuesday after the company said an independent expert advisory group gave a positive review of a late-stage clinical trial of its cystic fibrosis drug. The group, the Data and Safety Monitoring Board, said it had “no concerns” with data to date on the phase 3 clinical trial for Sollpura in cystic fibrosis patients with pancreatic insufficiency and voted that the study continue without protocol or charter changes. Shares of Anthera dropped 7.9% over the last three months, compared with a 6.0% rise in the S&P 500 .
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
From:: Stock Market News